Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries

Camacho‐Soto, Alejandra; Gross, Anat; Nielsen, Susan Searles; Dey, Neelendu; Racette, Brad A.

doi:10.1016/j.parkreldis.2018.02.008

Cited by 65 publications

(71 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, fecal Calprotectin has been identified as a marker of activation of the gut immune system in PD patients [ 110 ]. Inflammatory bowel disease represents a risk factor to develop PD and this risk is significantly reduced in patients receiving anti-inflammatory therapy [ 111 , 112 ]. Additionally, the presence of α-Syn inclusions in the enteric system and vagal nerves has been detected in the very early stages of PD [ 113 ].…”

Section: Role Of Peripheral Inflammation: Novel Hypothesis For Pd mentioning

confidence: 99%

Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications

Pajares

Rojo

Manda

et al. 2020

Cells

391

296

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a common neurodegenerative disorder primarily characterized by the death of dopaminergic neurons that project from the substantia nigra pars compacta. Although the molecular bases for PD development are still little defined, extensive evidence from human samples and animal models support the involvement of inflammation in onset or progression. However, the exact trigger for this response remains unclear. Here, we provide a systematic review of the cellular mediators, i.e., microglia, astroglia and endothelial cells. We also discuss the genetic and transcriptional control of inflammation in PD and the immunomodulatory role of dopamine and reactive oxygen species. Finally, we summarize the preclinical and clinical approaches targeting neuroinflammation in PD.

show abstract

Section: Role Of Peripheral Inflammation: Novel Hypothesis For Pd mentioning

confidence: 99%

Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications

Pajares

Rojo

Manda

et al. 2020

Cells

391

296

View full text Add to dashboard Cite

show abstract

“…Ingestion of fermented milk for 4 weeks was proven to be effective in improving PD complications such as constipation [182]. Two studies have shown that anti-TNF therapy and immunosuppressants reduced PD risk [183,184]. However, there is very limited clinical evidence of the beneficial effects of probiotics in the treatment of PD and further evidences are needed.…”

Section: Parkinson's Diseasementioning

confidence: 99%

The progress of gut microbiome research related to brain disorders

Zhu

Jiang

et al. 2020

J Neuroinflammation

277

213

View full text Add to dashboard Cite

There is increasing evidence showing that the dynamic changes in the gut microbiota can alter brain physiology and behavior. Cognition was originally thought to be regulated only by the central nervous system. However, it is now becoming clear that many non-nervous system factors, including the gut-resident bacteria of the gastrointestinal tract, regulate and influence cognitive dysfunction as well as the process of neurodegeneration and cerebrovascular diseases. Extrinsic and intrinsic factors including dietary habits can regulate the composition of the microbiota. Microbes release metabolites and microbiota-derived molecules to further trigger host-derived cytokines and inflammation in the central nervous system, which contribute greatly to the pathogenesis of host brain disorders such as pain, depression, anxiety, autism, Alzheimer's diseases, Parkinson's disease, and stroke. Change of blood-brain barrier permeability, brain vascular physiology, and brain structure are among the most critical causes of the development of downstream neurological dysfunction. In this review, we will discuss the following parts: Overview of technical approaches used in gut microbiome studies Microbiota and immunity Gut microbiota and metabolites Microbiota-induced blood-brain barrier dysfunction Neuropsychiatric diseases ■ Stress and depression ■ Pain and migraine ■ Autism spectrum disorders Neurodegenerative diseases ■ Parkinson's disease ■ Alzheimer's disease ■ Amyotrophic lateral sclerosis ■ Multiple sclerosis

show abstract

“…It is important to underline at this point that only a very small fraction of IBD patients develops PD. In yet another case-control study enrolling patients aged 65 years or older with newly diagnosed PD (n = 89,790) and controls (n = 118,095), an inverse correlation between PD and IBD has been shown, suggesting that patients with IBD are less likely to develop PD [69]. All population studies were summarized in an elegant meta-analysis by Zhu et al, demonstrating 46% increased risk of PD in IBD patients compared to controls.…”

Section: Epidemiological Evidence For a Link Between Ibd And Pdmentioning

confidence: 99%

Inflammatory Bowel Diseases and Parkinson’s Disease

Brudek

2019

JPD

View full text Add to dashboard Cite

The etiology of Parkinson's disease (PD) is multifactorial, with genetics, aging, and environmental agents all a part of the PD pathogenesis. Widespread aggregation of the ␣-synuclein protein in the form of Lewy bodies and Lewy neurites, and degeneration of substantia nigra dopamine neurons are the pathological hallmarks of PD. Inflammatory responses manifested by glial reactions, T cell infiltration, and increased expression of inflammatory cytokines, as well as other toxic mediators derived from activated glial cells, are currently recognized as prominent features of PD. Experimental, clinical and epidemiological data suggest that intestinal inflammation contributes to the pathogenesis of PD, and the increasing number of studies suggests that the condition may start in the gastrointestinal system years before any motor symptoms develop. Patients with inflammatory bowel disease (IBD) have a higher risk of developing PD compared with non-IBD individuals. Gene association study has found a genetic link between IBD and PD, and an evidence from animal studies suggests that gut inflammation, similar to that observed in IBD, may induce loss of dopaminergic neurons. Based on preclinical models of PD, it is suggested that the enteric microbiome changes early in PD, and gut infections trigger ␣-synuclein release and aggregation. In this paper, the possible link between IBD and PD is reviewed based on the available literature. Given the potentially critical role of gastrointestinal pathology in PD pathogenesis, there is reason to suspect that IBD or its treatments may impact PD risk. Thus, clinicians should be aware of PD symptoms in IBD patients.

show abstract

Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries

Abstract: IBD is associated with a lower risk of developing PD.

Cited by 65 publications

References 25 publications

Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications

Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications

The progress of gut microbiome research related to brain disorders

Inflammatory Bowel Diseases and Parkinson’s Disease

Contact Info

Product

Resources

About